MULTIPLE ARTERIAL THROMBOSIS AFTER COVID-19 DISEASE UNDER ANTICOAGULANT THERAPHY: A CASE TREATED WITH HYBRIT INTERVENTION

Creative Commons License

Çalık E., Jalalzaı I., Erkut B.

INTERNATIONAL SCIENTIFIC RESEARCH CONGRESS DEDICATED TO THE 30TH ANNIVERSARY OF BAKU EURASIA UNIVERSITY, Baku, Azerbaycan, 28 Nisan 2022

  • Yayın Türü: Bildiri / Tam Metin Bildiri
  • Basıldığı Şehir: Baku
  • Basıldığı Ülke: Azerbaycan
  • Atatürk Üniversitesi Adresli: Evet

Özet

Abstract

Since the beginning of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-

2) pandemic, many reports have pointed to states of increased hypercoagulability during the

acute phase of the disease. It is known that the respiratory system is mainly affected by this

severe disease and coagulopathy plays an important role in high mortality rates.

We report a case of acute mesenteric ischemia due to celiac trunk and superior

mesenteric artery thrombosis along with acute lower extremity ischemia caused by saddle

embolism of iliac bifurcation and thrombosis of the left external iliac artery.

A 63-year-old female patient was discharged after being treated in the intensive care

unit for about 2 months in an another hospital due to a severe Covid-19 pneumonia and

accompanying submassive pulmonary embolism. The patient applied to the emergency

service with complaints of abdominal pain, weakness and pain in the left lower extremity 20

days after discharge. In the thorax+abdominal CT, celiac artery and superior mesenteric

artery thrombosis and thrombus hanging in the aortic lumen, accompanied by saddle

thrombosis of the aorta-iliac bifurcation and left external iliac artery thrombosis were

detected

The patient had hybrite intervention. Embolectomy was performed for aortic saddle and

left iliac artery emboli, and than percutaneous peripheral intervention for mesenteric

thrombosis. After the intervention, the patient was followed up in the clinic for two more

days. The pain in abdomen and lower extremities were resolved. She was discharged with

dual antiaggregant (aspirin 100 mg/day and clopidogrel 75 mg/day), and anticoagulant

(rivaroxaban 20 mg/day). The patient was well at the 6th month follow-up and had no

additional problems.

Treatment of multiple thrombosis after severe SARS-CoV-2 disease can be done easily

and safely with hybrid interventions. But large-scale studies are needed to better understand

the role of coagulopathy and anticoagulation therapy in the management of patients with

COVID-19 infection.

Keywords: Severe acute respiratory syndrome Coronavirus 2; Covid-19; multiple

arterial thrombosis; hybrit intervention.